Valuation: Exagen Inc.

Market Cap 156M 135M 126M 116M 219M 14.82B 222M 1.49B 581M 7.41B 585M 572M 24.55B P/E 2026 *
-9.7x
P/E 2027 * -13x
Enterprise Value 156M 135M 126M 116M 219M 14.82B 222M 1.49B 581M 7.41B 585M 572M 24.55B EV / Sales 2026 *
2.13x
EV / Sales 2027 * 1.94x
Free-Float
57.84%
Yield 2026 *
-
Yield 2027 * -
1 day+37.82%
1 week+44.94%
Current month+42.38%
1 month+42.07%
3 months+108.06%
6 months+83.76%
Current year+6.09%
1 week 4.38
Extreme 4.3801
6.83
1 month 4.05
Extreme 4.05
6.83
Current year 2.59
Extreme 2.59
6.83
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.9
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 17/10/2022
Director of Finance/CFO 57 01/09/2024
Chief Tech/Sci/R&D Officer - 23/06/2025
Director TitleAgeSince
Chairman 72 19/01/2023
Director/Board Member 63 30/07/2019
Director/Board Member 56 17/06/2021
Date Insider Type Main position Quantity % Market Cap.
2/24/26 A Sell

Chief Executive Officer

11,430 0.0504%
2/24/26 A Sell

Chief Financial Officer

1,584 0.0070%
10/16/25 A Sell

Chief Executive Officer

31,787 0.1445%
Change 5-day change 1-year change 3-year change Capi.($)
+37.82%+44.94%-27.12%+156.97% 156M
+1.79%+9.11%+101.50%+439.38% 39.41B
+1.60%-0.60%+18.38%+45.12% 25.27B
+0.72%-2.07%-19.50%-34.65% 7.68B
+3.62%+9.49%+24.12%+108.49% 5.44B
-0.32%+0.11%+17.99%+58.75% 3.32B
+2.84%+21.57%+187.30%+2.32% 2.09B
+4.48%+14.58%-34.56%+893.00% 2.11B
+0.51%+4.14%-10.29%-59.58% 1.9B
+1.27%+2.52%+22.31%+9.72% 1.86B
Average +5.62%+10.66%+28.01%+161.95% 8.92B
Weighted average by Cap. +1.83%+5.58%+54.27%+233.08%

Financials

2026 *2027 *
Net sales 73.24M 63.6M 59.3M 54.47M 103M 6.97B 104M 699M 273M 3.48B 275M 269M 11.54B 80.53M 69.92M 65.19M 59.89M 113M 7.66B 115M 769M 300M 3.83B 302M 296M 12.69B
Net income -16.1M -13.98M -13.03M -11.97M -22.65M -1.53B -22.89M -154M -60.07M -766M -60.46M -59.14M -2.54B -12.6M -10.94M -10.2M -9.37M -17.72M -1.2B -17.92M -120M -47.01M -599M -47.32M -46.28M -1.99B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
04/08/26 $6.450 +37.82% 2,745,988
03/08/26 $4.680 +3.31% 212,105
31/07/26 $4.530 -3.00% 106,474
30/07/26 $4.670 +7.36% 98,936
29/07/26 $4.350 -2.25% 188,561
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6.450USD
Average target price
9.714USD
Spread / Average Target
+50.61%

Quarterly revenue - Rate of surprise